Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.
about
A survey of laboratory and statistical issues related to farmworker exposure studiesAssessing arsenic exposure in households using bottled water or point-of-use treatment systems to mitigate well water contaminationSample size determination for fold-increase endpoints defined by paired interval-censored data.On methods to utilize HIV-RNA data measured by two different PCR assays.Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry.First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus.Mental Health Care for Youth: Predictors of Use are not always the same as Predictors of Volume.Estimation of smooth ROC curves for biomarkers with limits of detection.Determinants of temporal variability in NHEXAS-Maryland environmental concentrations, exposures, and biomarkers.Bayesian Empirical Likelihood Methods for Quantile Comparisons.Smooth ROC curves and surfaces for markers subject to a limit of detection using monotone natural cubic splines.
P2860
Q23911555-FF4D3BAA-E9D8-4CA3-9FD3-4A57FAE35BBFQ28386447-35FF9205-8B3A-432A-85E1-35C319EA0AADQ31052614-3806BD35-BB7C-4D74-B08E-B881FCBBE52EQ31161882-2654AFC1-1D40-466F-ADE6-E474FBC2B704Q34084316-960815DA-AE2B-4C42-9333-3CCE58442DDBQ34159418-9C359883-A649-4A53-B209-9CF729E96A91Q34324005-E19CA325-3A19-4732-9D66-45B3736CEC3BQ34419912-9AAB7FB6-94FA-454E-A532-48462B4297F7Q35034306-6BDD13F5-01D7-4A3F-ACD6-0EDD157009D1Q35474328-FEE6887C-50F2-4CF1-BE12-76FC938123A8Q37079262-6BB23536-A1A8-4F9F-AEB5-E1C262EFA168Q38635417-519610D1-6E04-4CE2-8007-1E493358A8F0Q45189251-FC57601C-1061-4A32-A0AB-40A45D843870Q50042241-5D9BCFF5-0B44-4A01-B190-9D6462E00CB2Q51236669-8405D87E-1E69-4B7C-8E1A-0A7B9668F8B5
P2860
Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Analysis and design issues for ...... ements in HIV clinical trials.
@ast
Analysis and design issues for ...... ements in HIV clinical trials.
@en
Analysis and design issues for ...... ements in HIV clinical trials.
@nl
type
label
Analysis and design issues for ...... ements in HIV clinical trials.
@ast
Analysis and design issues for ...... ements in HIV clinical trials.
@en
Analysis and design issues for ...... ements in HIV clinical trials.
@nl
prefLabel
Analysis and design issues for ...... ements in HIV clinical trials.
@ast
Analysis and design issues for ...... ements in HIV clinical trials.
@en
Analysis and design issues for ...... ements in HIV clinical trials.
@nl
P2860
P1476
Analysis and design issues for ...... ements in HIV clinical trials.
@en
P2093
P2860
P304
P356
10.1002/1097-0258(20001215)19:23<3171::AID-SIM619>3.0.CO;2-T
P407
P577
2000-12-01T00:00:00Z